Dabomb Protein Biotech Corporation (6578) Stock Statistics & Valuation Metrics

Dabomb Protein Biotech Corporation has a market cap or net worth of TWD 1.21B. The enterprise value is TWD 1.09B.

Market Cap

TWD 1.21B

Enterprise Value

TWD 1.09B

Dabomb Protein Biotech Corporation has 71,941,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

71,941,900

Owned by Insiders

―

Owned by Institutions

―

Dabomb Protein Biotech Corporation’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -2.64%.

Return on Equity (ROE)

-0.07

Return on Assets (ROA)

-0.06

Return on Invested Capital (ROIC)

-2.64%

Return on Capital Employed (ROCE)

-0.03

Revenue Per Employee

6.72M

Profits Per Employee

-1.51M

Employee Count

46

Asset Turnover

0.28

Inventory Turnover

12.62

The current PE Ratio of Dabomb Protein Biotech Corporation is -29.65. Dabomb Protein Biotech Corporation’s PEG ratio is 0.22.

PE Ratio

-29.65

PS Ratio

3.58

PB Ratio

1.20

Price to FCF

47.98

Price to Operating Cash Flow

30.13

PEG Ratio

0.22

In the last 12 months, Dabomb Protein Biotech Corporation had revenue of 309.33M and earned -69.34M in profits. Earnings per share was -0.96.

Revenue

309.33M

Gross Profit

69.03M

Operating Income

-28.18M

Pretax Income

-66.34M

Net Income

-69.34M

EBITDA

-22.25M

Earnings Per Share (EPS)

-0.96

In the last 12 months, operating cash flow was 40.36M and capital expenditures -15.02M, giving a free cash flow of 25.34M billion.

Operating Cash Flow

40.36M

Free Cash Flow

25.34M

Free Cash Flow per Share

0.35

Dabomb Protein Biotech Corporation pays an annual dividend of ―, resulting in a dividend yield of 2.37%

Dividend Per Share

―

Dividend Yield

2.37%

Payout Ratio

N/A

Free Cash Flow Yield

2.08%

Earnings Yield

-3.45%

Beta

0.06

52-Week Price Change

-16.34%

50-Day Moving Average

17.01

200-Day Moving Average

17.26

Relative Strength Index (RSI)

48.41

Average Volume (3m)

57.02K

Dabomb Protein Biotech Corporation upcoming earnings date is ―, TBA (Confirmed).

Last Earnings Date

Aug 03, 2026

Next Earnings Date

―

Ex-Dividend Date

―

Dabomb Protein Biotech Corporation as a current ratio of 2.67, with Debt / Equity ratio of 7.50%

Current Ratio

2.67

Quick Ratio

2.45

Debt to Market Cap

0.05

Net Debt to EBITDA

2.61

Interest Coverage Ratio

-9.18

In the past 12 months, Dabomb Protein Biotech Corporation has paid 3.00M in taxes.

Income Tax

3.00M

Effective Tax Rate

-0.05

Dabomb Protein Biotech Corporation EV to EBITDA ratio is 32.05, with an EV/FCF ratio of 45.17.

EV to Sales

3.37

EV to EBITDA

32.05

EV to Free Cash Flow

45.17

EV to Operating Cash Flow

28.36

Dabomb Protein Biotech Corporation has TWD 168.72M in cash and marketable securities with TWD 68.49M in debt, giving a net cash position of TWD 100.23M billion.

Cash & Marketable Securities

TWD 168.72M

Total Debt

TWD 68.49M

Net Cash

TWD 100.23M

Net Cash Per Share

TWD 1.39

Tangible Book Value Per Share

TWD 14.03

Gross margin is 16.52%, with operating margin of -6.34%, and net profit margin of -12.35%.

Gross Margin

16.52%

Operating Margin

-6.34%

Pretax Margin

-10.06%

Net Profit Margin

-12.35%

EBITDA Margin

10.52%

EBIT Margin

-1.13%

The average price target for Dabomb Protein Biotech Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

21.50%

EPS Growth Forecast

-4.09%